However, long-term ET raises concerns about further adverse events, including the incidence of endometrial cancer and pulmonary embolism with tamoxifen [42], osteoporosis, bone fracture, arthralgia, myalgia, and cardiovascular events with aromatase inhibitors [43, 44]. This evidence concerns the gene CYP19A1 and osteoporosis.